Parkside Financial Bank & Trust’s Ultragenyx Pharmaceutical RARE Stock Holding History

Parkside Financial Bank & Trust’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$435	Sell	13 -35	-73%	-$869	﹤0.01%	2619
2026 Q1	$1.01K	Sell	48 -84	-64%	-$1.89K	﹤0.01%	2355
2025 Q4	$3.04K	Hold	132	–	–	﹤0.01%	1961
2025 Q3	$3.97K	Buy	132 +121	+1,100%	+$3.63K	﹤0.01%	1802
2025 Q2	$400	Buy	+11	New	+$397	﹤0.01%	2620
2025 Q1	–	Sell	-6	Closed	-$253	–	2757
2024 Q4	$253	Buy	+6	New	+$298	﹤0.01%	2017
2023 Q3	–	Sell	-80	Closed	-$3.69K	–	2098
2023 Q2	$3.69K	Hold	80	–	–	﹤0.01%	1475
2023 Q1	$3.21K	Hold	80	–	–	﹤0.01%	1527
2022 Q4	$3.71K	Buy	+80	New	+$3.15K	﹤0.01%	1445
2022 Q3	–	Sell	-11	Closed	-$1K	–	1917
2022 Q2	$1K	Buy	+11	New	+$677	﹤0.01%	1749
2022 Q1	–	Sell	-2	Closed	–	–	1915
2021 Q4	$0	Sell	2 -3	-60%	-$244	﹤0.01%	1901
2021 Q3	$0	Buy	+5	New	+$452	﹤0.01%	1831

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Parkside Financial Bank & Trust's RARE Position: Q2 2026 in Review

Parkside Financial Bank & Trust reduced its Ultragenyx Pharmaceutical (RARE) stake by 73% in Q2 2026, selling an estimated $869 and leaving 13 shares worth $435. The position accounts for ﹤0.01% of the portfolio, ranked #2619.

Parkside Financial Bank & Trust first reported a position in RARE in Q3 2021 and has held it in 12 quarters since. The position peaked at $3.97K in Q3 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Parkside Financial Bank & Trust held 13 shares of Ultragenyx Pharmaceutical worth $435 as of Q2 2026.
Parkside Financial Bank & Trust sold 35 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $869.
Ultragenyx Pharmaceutical made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2619 holding.
Parkside Financial Bank & Trust first reported a position in Ultragenyx Pharmaceutical in Q3 2021 and has held it in 12 quarters since.
Parkside Financial Bank & Trust's Ultragenyx Pharmaceutical position peaked at $3.97K in Q3 2025.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.